Skye details new clinical, preclinical data, including initiation of higher-dose CBeyond Expansion Study.
Skye Bioscience Inc reports fiscal Q4 2025 results with non-GAAP EPS $-0.36 (-50% YoY) and revenue $0, misses EPS but beats revenue estimates
- Skye Bioscience also reported full-year 2025 financial results alongside its fiscal Q4 2025 report.
- Company detailed new clinical and preclinical data, including initiation of a higher-dose CBeyond Expansion Study.
- Management said $25.7 million in cash and investments funds operations through Q4 2026 and excludes planned Phase 2b costs.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.